An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101

Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies. LOXO-101 is an orally administered inhibitor of the TRK kinase, and is highly selective only for th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Doebele, Robert C., Davis, Lara E., Vaishnavi, Aria, Le, Anh T., Estrada-Bernal, Adriana, Keysar, Stephen, Jimeno, Antonio, Varella-Garcia, Marileila, Aisner, Dara L., Li, Yali, Stephens, Philip J., Morosini, Deborah, Tuch, Brian B., Fernandes, Michele, Nanda, Nisha, Low, Jennifer A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635026/
https://ncbi.nlm.nih.gov/pubmed/26216294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0443
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi